Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2019 Apr 24;18(6):1036–1044. doi: 10.1158/1535-7163.MCT-18-1206

Fig. 5. SF2523 reduces tumor growth, immunosuppression and promotes anti-tumor adaptive immune responses.

Fig. 5.

A, Tumor volume of LLC inoculated subcutaneously in WT mice (n=12/group) treated with 40mg/kg JQ1 or SF2523. Data analyzed by one way ANOVA using Tukey’s post-hoc test ** P<0.01, *** P<0.001. B, CD11b+Gr1− and CD11b+Gr1+ cells infiltrated in LLC tumors treated with JQ1 or SF2523 (n=3), two way ANOVA with Bonferroni posttests *** p<0.001 C, MHCII+ TAMs infiltrated in the JQ1 or SF2523 treated LLC tumors, data in B and C, one-way ANOVA using Tukey’s post-hoc test,* p< 0.05, ** p< 0.01, *** p<0.001. D, Relative expression levels of immune regulatory genes in CD11b+ cells isolated from JQ1 or SF2523 treated LLC tumors mentioned in A subpanel. E, Flow cytometric quantification of CD3+, CD4+ and CD8+ T cells in the LLC tumors treated with JQ1 or SF2523. F, Relative mRNA expression of Ifng and Gzmb from JQ1- and SF2523-treated tumors. G, Tumor volume of CT26 tumors depleted with anti-CD8 antibody or isotype control antibody and treated with 40mg/kg JQ1 or 40 mg/kg SF2523. H & I, Flow cytometric quantification of CD4+, CD8+ (H, upper and lower panel) and CD4+FOXP3+ (I) T cells in the CT26 tumors treated with JQ1 or SF2523